Drugs.com - Clinical Trials

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma

Lund, Sweden – April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

May 7, 2025 - 04:36
 0
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma
Lund, Sweden – April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...
Read More

Tags:

Previous Article

Another gold thread spun in tangled web of West Africa-focused miners and investors

Next Article

Qantas to launch new Perth-Johannesburg flights

Related Posts

Orforglipron Demonstrated Statistically Significant Efficacy Results and a Safety Profile Consistent with Injectable GLP-1 Medicines in Successful Phase 3 Trial

Orforglipron Demonstrated Statistically Significant Eff...

Apr 26, 2025  0

Sarepta Therapeutics Shares Safety Update on Elevidys

Sarepta Therapeutics Shares Safety Update on Elevidys

Apr 26, 2025  0

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim Starts Phase II Study of its Poten...

May 6, 2025  0